Dako A/S (Acquired by Agilent Technologies, Inc.) and Omnyx, LLC Launch Digital Pathology Solution for Breast Cancer Diagnostics

GLOSTRUP, DENMARK--(Marketwired - August 30, 2013) - Dako, an Agilent Technologies Company and worldwide provider of cancer diagnostics, and Omnyx, LLC (a joint venture of GE Healthcare and the University of Pittsburgh Medical Center) a leader in digital pathology, announced today that they are launching clinical image analysis for digital pathology in Europe.

By providing quantitative results for HercepTest, Dako and Omnyx enable a confident diagnosis, with an overall aim of supporting pathologists in generating accurate, objective and reproducible diagnostic results.

As part of the collaboration which began in 2010, Dako has used its expertise in staining and image analysis to develop algorithms that are incorporated into the Omnyx digital pathology platform as part of Omnyx's overall strategy of providing pathologists with a comprehensive digital workflow. The HercepTest image analysis tool is now accessible in the Omnyx system and has been specifically customized for Dako's breast cancer prognostic markers.

"Omnyx envisions a future where image analysis and workflow empower pathologists to make confident clinical decisions ultimately leading to better patient care," said Jim LaFrance, CEO of Omnyx. "Our partnership with Dako allows us to offer image analysis to clinicians who use Dako tests. Image analysis for prognostic markers within the Omnyx Integrated Digital Pathology workflow provides pathologists with a powerful set of tools to improve both accuracy and efficiency."

Digital pathology converts glass slides into digital images and efficiently manages the resulting image data. It enables pathologists to improve productivity by providing a virtual means of reviewing tissue sections without handling traditional glass slides, and it offers digital image analysis tools to help pathologists interpret tissue-based test results objectively. Digital pathology holds tremendous potential for standardizing test interpretation and enabling greater accuracy in cancer diagnostics.

"With this offering, Dako and Omnyx support pathologists in making confident, efficient diagnoses based on both subjective and quantitative measures," said Jakob Mohr Christensen, vice president of Global Marketing at Dako. "Additionally, the algorithms link digital scanners to Dako reagents and staining instruments, which give customers a complete and integrated solution. Dako is committed to continually improving patient care by finding ways to further enhance the standards and accuracy in cancer diagnostics."

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company's 20,500 employees serve customers in more than 100 countries. Agilent had revenues of $6.9 billion in fiscal 2012. Information about Agilent is available at www.agilent.com.

About Omnyx

Omnyx, LLC is a joint venture of GE Healthcare and the University of Pittsburgh Medical Center with locations in Pittsbugh, Pa., and Piscataway, N.J. The company is developing an enterprise platform to transform the scope of pathology to an all-digital workflow. The company will sell their digital pathology platform to clinical labs and offer an enterprise software platform for image management, workflow automation, image analysis algorithms and system integration along with its high speed whole-slide scanners. Close collaboration with pathologists at UPMC and other institutions along with their relationship with GE Healthcare allows Omnyx to focus its innovation on the needs of anatomic pathologists worldwide. Omnyx digital pathology products are currently in development and have not yet been cleared by the U.S. Food and Drug Administration. Information about Omnyx is available at www.omnyx.com.

About Dako - An Agilent Technologies Company

Dako, based in Denmark, is a global leader in tissue-based cancer diagnostics. Hospital and research laboratories worldwide use Dako's reagents, instruments, software and expertise to make accurate diagnoses and determine the most effective treatment for cancer patients. Dako, with 1,200 employees, operates in more than 100 countries. Dako became part of Agilent Technologies on June 21, 2012. Information about Dako is available at www.dako.com.

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Dako Denmark A/S via Thomson Reuters ONE

[HUG#1726095]